Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients

医学 倾向得分匹配 内科学 肿瘤科 结直肠癌 总体生存率 队列 免疫疗法 贝伐单抗 护理标准 微卫星不稳定性 比例危险模型 回顾性队列研究 性能状态 无进展生存期 癌症 队列研究 转移 生存分析 多元分析 化疗 瑞戈非尼
作者
Guglielmo Vetere,Emerik Österlund,Mahmoud Yousef,Songwit Payapwattanawong,Giulia Maddalena,Jumanah Alshenaifi,Kristin D Alfaro,Mark Knafl,Van K Morris,Christine M. Parseghian,Kanwal P S Raghav,Robert A Wolff,Arvind Dasari,Michael J. Overman,Scott Kopetz,John Paul Shen
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:14 (9): e015414-e015414
标识
DOI:10.1136/jitc-2026-015414
摘要

Background Immune checkpoint inhibitors (ICIs) have limited efficacy in proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC). However, selected patients with specific metastatic patterns may derive benefit. Methods Patients with chemorefractory pMMR/MSS mCRC treated with ICI-based regimens were retrospectively identified. A comparison cohort treated with trifluridine/tipiracil±bevacizumab, regorafenib, or fruquintinib as standard of care (SOC) was generated through 1:1 propensity score matching by age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), liver metastases (present/absent), and RAS/BRAF status. Overall survival (OS) was compared using Cox regression. Results A total of 354 patients treated with ICIs and 354 treated with SOC were matched. Median age was 55 years, 52% male, 32% ECOG PS 0, 30% right-sided, and 69% RAS mutated in both groups, while 61% and 60% had liver metastases, respectively. Median OS (mOS) was 10.8 months with ICIs and 9.0 months with SOC (HR 0.76, 95% CI 0.64 to 0.92, p=0.004). In patients without liver metastases, mOS was longer with ICIs than SOC (19.1 vs 13.2 months, HR 0.59, 95% CI 0.43 to 0.80, p<0.001), whereas outcomes were similar in patients with liver metastases (6.4 vs 6.5 months, p=0.303). In univariable analyses, age, sex, primary tumor site, and RAS / BRAF status were not associated with OS. Treatment with ICIs, absence of liver metastases, one prior line of therapy, less than three metastatic sites, and ECOG PS 0 were associated with the most favorable outcomes in univariable and multivariable models. Conclusions In chemorefractory pMMR/MSS mCRC without liver metastases, ICI-based regimens yielded longer OS than SOC. Further investigation of ICIs in this patient population is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
刚刚
heaven发布了新的文献求助10
1秒前
1秒前
英姑的应助被不敢说话采纳,获得10
1秒前
Mr_Qiu发布了新的文献求助10
2秒前
文化部发布了新的文献求助10
2秒前
Felix发布了新的文献求助10
2秒前
orixero的应助被小岛艺术家采纳,获得10
3秒前
3秒前
医学小生完成签到,获得积分10
3秒前
向分公司发布了新的文献求助10
3秒前
1加发布了新的文献求助10
4秒前
4秒前
4秒前
6秒前
大个的应助被王小彤采纳,获得10
6秒前
6秒前
余香的应助被慕念采纳,获得10
6秒前
耶耶业发布了新的文献求助10
7秒前
lijing327发布了新的文献求助30
7秒前
长情平彤完成签到,获得积分10
8秒前
王发发布了新的文献求助10
8秒前
李李李发布了新的文献求助10
8秒前
Hello的应助被科研新牛马采纳,获得10
8秒前
9秒前
赫江涛发布了新的文献求助10
9秒前
9秒前
红丽阿妹完成签到,获得积分10
10秒前
11秒前
JamesPei的应助被愤怒的尔蓉采纳,获得10
11秒前
12秒前
12秒前
他山之鱼发布了新的文献求助30
12秒前
13秒前
Young发布了新的文献求助10
13秒前
冂xx易云完成签到,获得积分10
13秒前
亦天凛发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156